- Home
- RPTX vs MNOV Comparison
RPTX vs MNOV Comparison
Compare RPTX & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPTX | MNOV |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.4M | 76.5M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RPTX | MNOV |
|---|---|---|
| Price | $2.18 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $3.50 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.2M | 134.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,870,000.00 | $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.89 | $1.13 |
| 52 Week High | $4.07 | $2.37 |
Technical Indicators
Market Signals| Indicator | RPTX | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 56.46 |
| Support Level | $2.15 | $1.50 |
| Resistance Level | $2.24 | $1.60 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 57.35 | 65.00 |
Price Performance
Historical ComparisonAbout RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.